Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for adjuvant treatment of resected non-small-cell lung cancer.
Status In progress
Technology type Medicine
Decision Selected
Process STA 2018
ID number 3852

Provisional Schedule

Committee meeting: 2 07 July 2022
Expected publication 14 September 2022

Project Team

Project lead Celia Mayers

Email enquiries

External Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter


Companies sponsors • Roche (atezolizumab)
Others • Department of Health and Social Care
  • NHS England
  • Welsh Government
Professional groups • Association of Cancer Physicians
  • British Thoracic Society
  • Cancer Research UK
  • Royal College of Physicians
Comparator companies • Accord Healthcare (cisplatin, docetaxel, gemcitabine, vinorelbine) (confidentiality agreement not signed, not participating)
  • AstraZeneca (osimertinib)
  • Eli Lilly (pemetrexed) (confidentiality agreement not signed, not participating)
  • Hospira UK (cisplatin,
  docetaxel, gemcitabine) (confidentiality agreement not signed, not participating)
  • Medac GmbH (vinorelbine) (confidentiality agreement not signed, not participating)
  • Seacross Pharmaceuticals (docetaxel,
  pemetrexed) (confidentiality agreement not signed, not participating)
General commentators • All Wales Therapeutics and Toxicology Centre
  • British National Formulary
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Scottish Medicines Consortium
  • Welsh Health Specialised Services Committee
Relevant research groups • Institute of Cancer Research


Key events during the development of the guidance:

Date Update
23 June 2022 Following the first committee meeting for this appraisal on 5 May 2022, the committee was unable to develop recommendations for this appraisal without the submission of additional analyses from the company. NICE has now received additional analyses from the company and this topic will be discussed at a committee meeting on Thursday 7 July 2022.
05 May 2022 Committee meeting
02 September 2021 We recently contacted all stakeholders for the appraisal of atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852] regarding a delay to this topic for operational reasons. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer has now been rescheduled into the work programme. The appraisal is due to start late August 2021 and will be discussed at committee in early May 2022. The new timelines are subject to the work programme capacity and we will continue to review our plans in collaboration with the company and update our stakeholders accordingly.
25 August 2021 Invitation to participate
13 May 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
23 March 2021 - 22 April 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
23 March 2021 In progress. DHSC referral received: 05/08/2020

For further information on our processes and methods, please see our CHTE processes and methods manual